Abatacept
Severe
Database
Drug interaction classified as: synergy.
Source: DDInter
Drug reference
Golimumab
Monoclonal Antibody · Treatment of inflammatory bowel disease
Monoclonal AntibodyTreatment of inflammatory bowel disease
CDSCO approvedSchedule H
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactionssee all 12 →
- AbataceptSevereDatabaseDDInter
- AbemaciclibSevereDatabaseDDInter
- AcalabrutinibSevereDatabaseDDInter
- AdalimumabSevereDatabaseDDInter
Mechanism
Golimumab is a monoclonal antibody. It acts by inhibiting the pro-inflammatory cytokine, tumor necrosis factor alpha (TNF-alpha).
Indications
Moderate-to-severe active ulcerative colitis (after inadequate response to conventional treatment options, or if conventional treatment is not tolerated or contraindicated)moderately to severely active rheumatoid arthritisactive psoriatic arthritisankylosing spondylitismoderately to severely active ulcerative colitismoderate-to-severe ulcerative colitis in adults not responsive or intolerant of traditional therapy
Dosing
- Adult
- corticosteroid dose cannot be reduced. Azathioprine p. 881 or mercaptopurine p. 963 [unlicensed indications] can be added to a corticosteroid or budesonide to induce remission. In patients who cannot tolerate azathioprine or mercaptopurine or in whom thiopurine methyltransferase (TPMT) activity is deficient, methotrexate p. 963 can be added to a corticosteroid.…
Pharmacokinetics
Half-life
Approximately 14 days.
Side effects
Serious
- increased risk of serious infections
- increased risk of lymphoma and other malignancies
- infection (from immunosuppression, increased with steroids)
- reactivation of tuberculosis
- opportunistic infections with subsequent dissemination
- increased incidence of non-Hodgkin lymphoma (causal role not established)
- drug-induced lupus
- multiple sclerosis–like syndrome
- nonmelanoma skin cancer
Drug interactions
Abemaciclib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Acalabrutinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Adalimumab
Severe
Database
Drug interaction classified as: synergy.
Source: DDInter
Aflibercept
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Aldesleukin
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Altretamine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Anakinra
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Antithymocyte Immunoglobulin (rabbit)
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Asparaginase Escherichia Coli
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Atezolizumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Avapritinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Related guidelines
Other Monoclonal Antibody drugs
Ask House about Golimumab
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, BNF·Verified: 2026-05-13 · House clinical team